OASM - Oasmia Pharmaceutical AB (publ)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9999
0.0000 (0.0000%)
At close: 2:26PM EST
Stock chart is not supported by your current browser
Previous Close0.9999
Open0.9999
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.9999 - 0.9999
52 Week Range0.8000 - 3.7000
Volume100
Avg. Volume7,934
Market Cap59.886M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3630
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 6, 2017
    Capital Cube12 days ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2018 By the Numbers : December 6, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Oasmia Pharmaceutical AB – Onconova Therapeutics Inc., Ono Pharmaceutical Co., Ltd. Unsponsored ADR and Ophthotech Corp. (ONTX-US, OPHLY-US and OPHT-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
    Capital Cube3 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Oasmia Pharmaceutical AB – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Ohr Pharmaceutical, Inc. (OMED-US, OMER-US and OHRP-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017
    Capital Cube5 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended April 30, 2017. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of USD -4.71 million. Gross margins narrowed from -51,783.05% to -85,334.09% compared to the same period last year, operating (EBITDA) margins now -82,834.09% from -49,876.27%. Change in operating ... Read more (Read more...)

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017
    Capital Cube9 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q3, 2017 By the Numbers : March 22, 2017

    Categories: Yahoo Finance Get free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended January 31, 2017. We analyze the earnings along side the following peers of Oasmia Pharmaceutical AB – Ohr Pharmaceutical, Inc., OncoMed Pharmaceuticals, Inc. and OncoGenex Pharmaceuticals, Inc. (OHRP-US, OMED-US and OGXI-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : January 19, 2017
    Capital Cube11 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q2, 2017 By the Numbers : January 19, 2017

    Categories: Yahoo Finance Get free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended October 31, 2016. Highlights Summary numbers: Revenues of USD 0.01 million, Net Earnings of USD -4.74 million. Gross margins widened from -78,861.54% to -64,394.64% compared to the same period last year, operating (EBITDA) margins now -62,369.64% from -76,528.85%. Change in operating ... Read more (Read more...)